Distinguishing dementia with Lewy bodies from Alzheimer’s disease using biomarker imaging techniques

Takeaway

  • For differentiation of dementia with Lewy bodies (DLB) from Alzheimer’d disease (AD), 123I-metaiodobenzylguanidine cardiac scintigraphy (MIBG) is not superior to 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP-CIT) SPECT imaging.

Why this matters ?

  • DLB is commonly misdiagnosed, impacting clinical management and carer wellbeing; validation of a diagnostic marker such as MIBG could help address this pervasive issue.